Men undergoing screening through PSA measurement have a reduction in neoplastic mortality. However, frequent biopsies and diagnosis of low-grade cancer are common due to PSA’s low specificity. A urine test, MPS2, with 18 genes targeting high-grade cancer outperforms PSA testing. MPS2 has a sensitivity of 95% for high-grade cancer, reducing unnecessary biopsies and detecting aggressive tumors. While the study has limitations, further research is needed to confirm results. Implementing MPS2 could reduce unnecessary tests and provide long-term benefits for prostate cancer screening. This test could be a practical option for risk stratification and early diagnosis in patients with high PSA levels.
Source link
Urine Test Could Prevent Unnecessary Prostate Biopsies
